SGS’ Post

The pharmaceutical industry has long focused on a narrow set of well-characterized targets, leading to intense competition and rapid development cycles. But new drug modalities are significantly broadening the druggable space, making previously challenging targets accessible. Have you signed up to our upcoming webinar? Discussions to be covered include: • Trends that have led to intense competition around a small pool of protein targets • How innovative new drug modalities are significantly broadening the druggable space • Why mass spectrometry-based discovery proteomics is ideally suited for the new ‘golden era’ of target identification, supporting novel discovery of drug targets in the previously undruggable realms of the proteome ▶️ Watch live or on-demand by registering here >> https://hubs.la/Q02C13KK0 #DiscoveryProteomics #TargetIdentification #ProteinTargets #DrugModalities #DrugTargets #MassSpectrometry Sapient Mo Jain, MD PhD Jonathan Usuka Carla Nieser Sign-up for our free newsletter: https://hubs.la/Q02C13r20

The pharmaceutical industry has long focused on a narrow set of well-characterized targets, leading to intense competition and rapid development cycles. But new drug modalities are significantly broadening the druggable space, making previously challenging targets accessible. Have you signed up to our upcoming webinar? Discussions to be covered include: • Trends that have led to intense competition around a small pool of protein targets • How innovative new drug modalities are significantly broadening the druggable space • Why mass spectrometry-based discovery proteomics is ideally suited for the new ‘golden era’ of target identification, supporting novel discovery of drug targets in the previously undruggable realms of the proteome ▶️ Watch live or on-demand by registering here >> https://hubs.la/Q02C13fN0 #DiscoveryProteomics #TargetIdentification #ProteinTargets #DrugModalities #DrugTargets #MassSpectrometry Sapient Mo Jain, MD PhD Jonathan Usuka Carla Nieser Sign-up for our free newsletter: https://hubs.la/Q02C13cV0

🔬 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐂𝐞𝐥𝐥 𝐋𝐲𝐬𝐢𝐬 𝐚𝐧𝐝 𝐃𝐢𝐬𝐫𝐮𝐩𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭! 🔬 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞:https://lnkd.in/dSFgiAn7 Revolutionary developments in the Cell Lysis and Disruption market are changing the face of cellular investigation. 🚀 Our knowledge of the architecture and functions of cells is expanding along with technology. 🌐 𝑺𝒕𝒂𝒚 𝒂𝒉𝒆𝒂𝒅 𝒐𝒇 𝒕𝒉𝒆 𝒄𝒖𝒓𝒗𝒆 𝒘𝒊𝒕𝒉 𝒕𝒉𝒆 𝒍𝒂𝒕𝒆𝒔𝒕 𝒊𝒏𝒏𝒐𝒗𝒂𝒕𝒊𝒐𝒏𝒔:https://lnkd.in/dX2aspuK Key Highlights: ✨ [Highlight a specific breakthrough or innovation in the market.] 🔍 Enhanced Cell Lysis Techniques 🔬 Revolutionary Disruption Technologies 🧬 Applications in Genomic Research and Biopharmaceuticals 📌𝐓𝐨𝐩 𝐊𝐞𝐲𝐩𝐥𝐚𝐲𝐞𝐫: Thermo Fisher Scientific Merck Group KGaA F. Hoffmann-La Roche Ltd QIAGEN NV Becton Dickenson Dickinson and Company Others. #CellLysis #DisruptionTechnologies #BiotechInnovation #LifeSciences #GenomicResearch #LinkedIn #ScienceandTechnology #Biopharmaceuticals #InnovationInScience

🎤 Join us for the highly anticipated session... Strategies for Production of Oligonucleotide Conjugates, taking place on the New Modalities track at the Oligonucleotide Therapeutics Xchange, Boston 🎤 Session Highlights: 🌟 Effect of conjugation site on process 🌟 Impact of conjugate on chromatography 🌟 Analytical implications 👨🔬 Presenter: Benjamin Thompson, PhD 💼 Process Development Project Leader, Nitto Avecia With over six years at Nitto Avecia, Benjamin has been at the forefront of process development for various oligonucleotide programs, from early to late-phase candidates. He excels in managing laboratory work and supporting the seamless transfer and execution of processes at large scales. 📅 Date: June 21, 2024 🕦 Time: 11:25 AM – 12:25 PM 📍 Location: Hilton Woburn Hotel, Boston ✍ Register now for your COMPLIMENTARY pass! https://bit.ly/3wYHLnQ ✍ * Agenda subject to change 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 #Biotechnology #Oligonucleotide #ProcessDevelopment #Pharmaceuticals #Networking #NittoAvecia #Innovation #Chromatography #LifeSciences #BioPharma #DrugDevelopment #PharmaManufacturing #AnalyticalChemistry #PharmaEvents #ScientificResearch #BostonEvents #hubXchange #Roundtable #FreePass #RegisterNow #ComplimentaryPass

The pharmaceutical industry has long focused on a narrow set of well-characterized targets, leading to intense competition and rapid development cycles. But new drug modalities are significantly broadening the druggable space, making previously challenging targets accessible. Have you signed up to our upcoming webinar? Discussions to be covered include: • Trends that have led to intense competition around a small pool of protein targets • How innovative new drug modalities are significantly broadening the druggable space • Why mass spectrometry-based discovery proteomics is ideally suited for the new ‘golden era’ of target identification, supporting novel discovery of drug targets in the previously undruggable realms of the proteome ▶️ Watch live or on-demand by registering here >> https://hubs.la/Q02C13Nv0 #DiscoveryProteomics #TargetIdentification #ProteinTargets #DrugModalities #DrugTargets #MassSpectrometry Sapient Mo Jain, MD PhD Jonathan Usuka Carla Nieser Sign-up for our free newsletter: https://hubs.la/Q02C13Qj0

In search of the 2023 Annual Meeting Highlights? Interested in Fanzor, RNAi or CircRNA? OTS has a steady stream of current, advanced science topics at https://lnkd.in/gsS-i4yz (And don't forget the Archive of articles under Science News.) #ots #oligotherapeutics #oligonucleotide #biotechnology #science #research #biochemistry #pharma #health #cellbiology #pharmaceuticals #currentscience

SEMINAR ALERT: Analytica pharma day 2024 by SCIEX FUELING YOUR ANALYTICAL WORKFLOWS WITH SCIENCE April 10, 2024 | 3:00 p.m.–5:00 p.m. CET Location: Conference room A32, Hall A3, Messe München Trade-Fair Center, Munich REGISTER: https://lnkd.in/dmXWaT7n The SCIEX and Phenomenex teams have been working and learning with our CUSTOMERS for answering the questions they might have in what concerns to the drug discovery and drug development of drugs. Now we want to share all the science we´ve understood with all the people attending to ANALYTICA. Here you have the topics we will cover: 15:00 – 15:30. Unveiling the latest HTS technology 15:30 – 16:00. Nitrosamines in drug products: overcoming sample preparation challenges via SPE for simultaneous quantification of 13 n-nitrosamines in various drugs 16:00 – 16:30. Analytical insights into nitrosamine drug substance related impurities (NDSRIs) 16:30 – 17:00. Structural elucidation of conjugation drug metabolites by utilizing novel electron-activated dissociation (EAD) Thanks to our speakers, Kristin Von Czapiewski, Heiko Behr and Axel Besa After the meeting you can join the Danaher Corporation booth where we´re sharing knowledge and experiences and some refreshments together with Phenomenex, Leica Microsystems and Beckman Coulter Life Sciences... and more! #lcms #pharmaceuticalindustry #drugdiscovery #drugdevelopment #hts #highthroughputscreening #drugmetabolites #drugmetabolism #drugcatabolism #metid #metabolitecharacterization #glucoronides #acylglucoronides #impurityprofiling #drugimpurities #ndsri #nitrosamine #qqq #qtof #hrms #ead #zenotof #triplequad #sciex #phenomenex

🗣️ Meet our facilitator, Firoz Antia 🚀 Get ready to dive deep into the Manufacturing track, at our upcoming Oligonucleotide Therapeutics Xchange 2024, Boston, where we'll tackle the downstream manufacturing challenges for synthetic oligonucleotides: 💥 Chromatography, Desalting, and Isolation 💥 Conjugation 💥 Annealing for Double-Stranded Products 💥 Analytical Characterization 🕰️ Time: 09:05 – 10:05 🗓️ Date: June 21st, 2024 📍 Location: Woburn Hilton Hotel, 2 Forbes Road, Woburn, US 🔑 Reserve your free spot now! https://bit.ly/3wYHLnQ 📢 We're thrilled to have Firoz Antia, Executive Director and Head of Oligonucleotide Development at Biogen, as a facilitator. With over two decades of expertise in drug development, process engineering, and manufacturing, Firoz brings invaluable insights into the latest advancements in oligonucleotide therapeutics. 🎯 Don't miss this opportunity to gain expert knowledge and network with industry leaders! Register now to secure your spot! * Agenda subject to change 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 #OligonucleotideTherapeutics #BiotechEvents #PharmaceuticalManufacturing #BiotechLeadership #OligonucleotideDevelopment #DrugDevelopment #TherapeuticsInnovation #LifeSciences #BostonEvents #Biopharmaceuticals #NetworkingOpportunity #BioPharmaCommunity #hubXchange #Roundtable #FreePass #RegisterNow #ComplimentaryPass

At #Alphabioregen, we are dedicated to transforming research through our innovative products and solutions. Our mission is to empower scientists and researchers with tools that enhance the #quality and #reliability of their work. We proudly offer a comprehensive range of Mammalian and Immortalized Cell Lines, Culture Media, Buffers, and advanced 3Dsupportingproducts, including 3D human and animal tissues.  What sets Alphabioregen apart is the exceptional reproducibility and relevance of our cell lines, which closely mimic human biology. This ensures that your research is not only efficient but also grounded in real-world #applicability. Our products are designed to meet the highest standards of #scientificintegrity, allowing you to focus on what truly matters—your research outcomes. For Example, Our #AlphaBioCoat #Coating #Solution Cat.#AC001 is being utilized for cell #growth and #expansion But don't just take our word for it. Our existing customers have shared testimonials highlighting the significant improvements they've experienced in their research projects thanks to our offerings. For instance, a recent case study showcased how a leading pharmaceutical company achieved groundbreaking results in drug development by incorporating our Mammalian cells into their studies.  Join us in our commitment to scientific advancement, and let Alphabioregen be your partner in progress. #MammalianCells #Alphabioregen #ScientificAdvancement #AlphaBioCoat #ScientificIntegrity

The highly popular poster presented at WRIB 2024 by Jing L., Principal Scientist on Anti-Drug Antibody (ADA) Assay for Xpro 1595, A Self-Assembling Trimer: Alternative to Standard Bridging Approach is now available for viewing here with no waiting! https://bit.ly/4cDA0Dx #drugmetabolism #pharmacokinetics #lifescience #invitro #biotransformation #dmpk #pharma #biotech #research #drugdevelopment #bioanalysis #bioanalytical #immunoassay #lcmsms #lcms #hrms #pharma #adme #oligonucleotides #monoclonalantibodies #rnabasedtherapeutics